HonorHealth Research News

Explore news and research from the HonorHealth Research Institute that is accelerating medical breakthroughs and improving patient outcomes.

Indoor portrait of Dr. unil Sharma
News

Dr. Sunil Sharma, a top physician-scientist at HonorHealth Research Institute, is named ‘Arizona Bioscience Researcher of the Year’

Dr. Sharma, who heads the Research Institute’s Center for Translational Science, is honored by the Arizona Bioindustry Association

Breakthroughs

All News Articles
A newly approved treatment is giving patients with advanced pancreatic cancer another option, and the physicians at HonorHealth Research Institute already have experience using it. The U.S. Food and Drug Administration has approved Rasonque (daraxonrasib), a once-daily pill for certain patients with metastatic pancreatic cancer. In a large clinical trial, patients receiving the targeted therapy survived nearly twice as long, on average, versus those receiving standard chemotherapy. Months before FDA approval, HonorHealth Research Institute was among the first centers in the country selected to provide the treatment through an expanded access program. That early access allowed eligible patients to receive the investigational therapy while giving the Research Institute's pancreatic cancer team valuable experience with the treatment before it became more widely available. “Daraxonrasib is the first medication to demonstrate success targeting KRAS, a genetic mutation in more than 90% of pancreatic cancers, and its effectiveness opens the door for more targeted strategies against pancreatic and other cancers in the future,” said Erkut Borazanci, MD, director of oncology at HonorHealth Research Institute. Erkut Borazanci, M.D., M.S., Director of Oncology at HonorHealth Research Institute, pictured in a professional office portrait.
Early access to new pancreatic cancer treatment expands hope
A man in a dark suit and purple tie stands indoors in front of a blurred background with large windows, as he prepares to present breakthrough research on synovial sarcoma immune-cell therapy.
Vaccine therapy offered at HonorHealth Research Institute shows potential for better treatment of advanced melanoma
HonorHealth Research Institute is among first in the nation to expand access to new drug that doubles survival of pancreatic cancer patients

Staff & Researchers

View All Staff & Researchers
Rachel Rogers
Steve Yozwiak
Nancy Stanisz
Javonna “Lucky” Calhoun

Patient Stories

All Patient Stories
Marlo Renee
JaneyGrace Dobbs

All News & Research

Filter By Topic